Market opportunity

Market sizing and competition

A bottom-up model from published epidemiology. Each patient group is sized separately - patients × annual price × share of patients treated at peak - across the major markets (US, Europe including the UK, Canada and Australia, plus Japan for Gorlin syndrome). Move the sliders to test the assumptions. These are estimates, not forecasts, and the rest of the world is excluded.

We focus on patients who keep developing new tumours. They are already under regular dermatology follow-up, carry the highest treatment burden and have the clearest case for a preventive medicine. The sliders start at our base case.

1. Gorlin syndrome and multiple basal cell carcinoma

Gorlin syndrome

Estimate 30,000-35,000
Small, identified population under specialist care
Peak sales
How we estimate the patient numbers
  • Prevalence about 1 in 31,000, from a UK population study after improved case finding; the older, widely quoted estimate was 1 in 57,000.Evans DG et al. Am J Med Genet A 2010; Farndon PA et al. Lancet 1992; Lo Muzio L. Orphanet J Rare Dis 2008;3:32.
  • Applied to a major-market population of about 1.04 billion (US 335M, EU 450M, UK 68M, Japan 124M, Canada 40M, Australia 27M) this gives about 33,000 people.
  • Range 30,000-35,000. The true diagnosed number may be lower, as milder cases go unrecognised.
  • Burden: median 8 new BCCs a year and a mean of 312 in a lifetime in the US patient registry; before vismodegib, patients in the Gorlin trial extension had about 28 surgeries a year.US basal cell nevus syndrome patient registry, burden of illness report; Tang JY et al. 2016.
  • Current drug treatment: NHS England funds vismodegib off-label for Gorlin syndrome with six or more BCCs (at least three of 5mm or more), on an intermittent schedule. It expected about 22 Gorlin patients a year in England to be treated.NHS England Clinical Commissioning Policy 1905 (210504P), July 2021.
  • In development: patidegib, a topical hedgehog-inhibitor gel (Sol-Gel), has completed a phase 3 trial preventing new facial BCCs in Gorlin syndrome, with results expected in late November 2026.ClinicalTrials.gov NCT06050122.

Multiple sporadic BCC

Estimate 1.0-1.5 million
Typical specialty uptake 10-25%
Peak sales
How we estimate the patient numbers
  • People diagnosed with a BCC each year: US about 2.0 million, UK about 184,000, rest of Europe about 0.7 million (our estimate, at about 150 per 100,000), Australia about 0.3 million and Canada about 0.06 million - about 3.2 million in total.Asgari MM et al. JAMA Dermatol 2015; Kwiatkowska M et al. Skin Health Dis 2021.
  • Recurrence: 44% of BCC patients develop another BCC within three years, and 53% within a median of eight years.Marcil I, Stern RS. Arch Dermatol 2000;136:1524-30; Spanish BCC multiplicity cohort, Actas Dermosifiliogr 2025.
  • We take 30-45% of each year's BCC patients as having had another BCC in the previous five years, giving 1.0-1.5 million.
  • Japan is excluded because BCC is uncommon there.
Segment 1 peak sales

2. Multiple cutaneous squamous cell carcinoma

Transplant recipients

All living transplant recipients - estimate 0.8-1.0 million
About one in five have recurrent skin cancer; about half of them treated
Peak sales
How we estimate the patient numbers
  • Living organ transplant recipients: about 350,000 in the US in 2017 (220,000 kidney, 84,000 liver, 32,000 heart, 14,000 lung), now over 400,000. In Europe about 39% of the 1,074 people per million on kidney replacement therapy live with a functioning kidney transplant - about 220,000 people in the registry's 530 million population - with liver, heart and lung recipients in addition. With Canada and Australia this gives an estimated 0.8-1.0 million.OPTN/SRTR Annual Data Reports; ERA Registry Annual Report 2022.
  • Risk: cSCC is 65-100 times more common than in the general population, and the risk keeps rising with time since transplant - it roughly triples over 20 years.Mayo Clinic Proceedings, skin cancer in solid organ transplant recipients; Krynitz B et al. Int J Cancer 2013.
  • How many develop skin cancer: in a UK cohort of 931 recipients (mean 10.3 years since transplant), cumulative incidence was 11%, 25%, 54% and 74% at 5, 10, 20 and 30 years; 29% had already had skin cancer and 66% of them had multiple tumours. Twenty-year cSCC incidence is about 34% in the UK and 40% in the Netherlands. In Queensland, 45% of kidney recipients had skin cancer after 11 years and 70% after 20.Harwood CA et al. Am J Transplant 2013; Bouwes Bavinck JN et al. Transplantation 1996;61:715-21; review, Adv Clin Exp Med 2025.
  • Recurrence: after a first skin cancer, 59% of kidney recipients had another within three years and 72% within five. 74% of transplant recipients with a first cSCC develop another within five years, rising to 92% after several.Wisgerhof HC et al. Transplantation 2010; Eggermont C et al. J Am Acad Dermatol 2024.
  • Rates are lower in the US, where more recipients have darker skin: cSCC incidence of 812 per 100,000 person-years across 10,649 recipients, and 2% with multiple cSCC over a mean of seven years in a single-centre cohort of 3,652.Garrett GL et al. JAMA Dermatol 2017;153:296-303; Puza CJ et al. JAMA Dermatol 2018;154:727-8.
  • Our base case takes about one in five living recipients across the major markets as having recurrent skin cancer (the UK figure, with higher rates in Australia and lower in the US), with about half of them treated at peak - 10% of all recipients. Patients immunosuppressed for other reasons (for example chronic lymphocytic leukaemia) are not included.

Multiple sporadic cSCC

Estimate 400,000-600,000
Typical specialty uptake 10-25%
Peak sales
How we estimate the patient numbers
  • People diagnosed with a cSCC each year: US 0.7-1.0 million, UK about 51,000, rest of Europe about 0.18 million (our estimate, at about 40 per 100,000), Australia about 0.2 million and Canada about 0.03 million - 1.2-1.5 million in total.Karia PS et al. J Am Acad Dermatol 2013;68:957-66; Rogers HW et al. JAMA Dermatol 2015; Kwiatkowska M et al. Skin Health Dis 2021.
  • Recurrence: in a nationwide Dutch cohort of 12,345 patients, 28% developed a second cSCC within five years of their first, and the risk climbed with each further tumour, to 67% after a fifth.Eggermont C et al. J Am Acad Dermatol 2024.
  • We take 28-40% of each year's cSCC patients as having had another cSCC within five years, giving 400,000-600,000. Transplant recipients are counted separately.
Segment 2 peak sales

3. Combined opportunity

If a single drug could prevent both BCC and cSCC, it could serve both groups, starting with BCC and extending to cSCC. Many patients develop both tumour types, so the combined figure removes the overlap - an estimated quarter of the multiple sporadic cSCC group also falls in the multiple BCC group - rather than adding the two segments together.

Combined peak sales
Ceiling (everyone treated)

The base case gives combined peak sales of about £8.8bn a year (segment 1 about £5.1bn, segment 2 about £4.1bn), within a ceiling of about £46bn. The route is sequential: Gorlin syndrome first (orphan, small trials, clearest unmet need), then multiple BCC, then cSCC in transplant and other high-risk patients.

Comparison with existing treatments

Current options either remove tumours after they appear, or prevent them only partly, briefly or at a cost in side effects. None prevents both BCC and cSCC with a treatment patients can stay on.

Key caveats

Sources